DOCSLIB.ORG

Concomitant Use of Nsaids Or Ssris with Noacs Requires Monitoring for Bleeding

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concomitant Use of Nsaids Or Ssris with Noacs Requires Monitoring for Bleeding Original Article Yonsei Med J 2020 Sep;61(9):741-749 https://doi.org/10.3349/ymj.2020.61.9.741 pISSN: 0513-5796 · eISSN: 1976-2437 Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding Min-Taek Lee1, Kwang-Yeol Park2, Myo-Song Kim1, Seung-Hun You1, Ye-Jin Kang1, and Sun-Young Jung1 1College of Pharmacy, Chung-Ang University, Seoul; 2Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. Purpose: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in patients with atrial fibrillation (AF) because of their effectiveness in preventing stroke and their better safety, compared with warfarin. However, there are concerns for an in- creased risk of bleeding associated with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) or selective sero- tonin reuptake inhibitors (SSRIs) with NOACs. In this study, we aimed to evaluate the risk of bleeding events in individuals taking concomitant NSAIDs or SSRIs with NOACs after being diagnosed with AF. Materials and Methods: A nested case-control analysis to assess the safety of NSAIDs and SSRIs among NOAC users with AF was performed using data from Korean National Health Insurance Service from January 2012 to December 2017. Among patients who were newly prescribed NOACs, 1233 cases hospitalized for bleeding events were selected, and 24660 controls were determined. Results: The risk of bleeding events was higher in patients receiving concomitant NSAIDs [adjusted odds ratio (aOR) 1.41; 95% confidence interval (CI) 1.24–1.61] or SSRIs (aOR 1.92; 95% CI 1.52–2.42) with NOACs, compared to no use of either drug, respec- tively. The risk of upper gastrointestinal bleeding was higher in patients receiving concomitant NSAIDs or SSRIs without proton pump inhibitors (PPIs) (NSAIDs: aOR 2.47; 95% CI 1.26–4.83, SSRI: aOR 10.8; 95% CI 2.41–2.48) compared to no use. Conclusion: When NSAIDs or SSRIs are required for NOAC users with AF, physicians need to monitor bleeding events and con- sider the use of PPIs, especially for combined use of both drugs or when initiating NOACs treatment. Key Words: ‌Non-vitamin K antagonist oral anticoagulants, atrial fibrillation, nested case-control study, hemorrhages, drug interactions INTRODUCTION the only OAC used for patients with AF.1 Because of the disad- vantages of using warfarin, including a narrow therapeutic range, Non-vitamin K antagonist oral anticoagulants (NOACs), intro- interaction with various foods and drugs, and the requirement duced to the market in 2010, have been used to treat patients of frequent monitoring for bleeding,3 NOACs have been pre- with atrial fibrillation (AF) instead of warfarin. About 85% of pa- ferred in clinical settings. tients with AF take oral anticoagulants (OACs),1 because treat- However, although to lesser degrees than warfarin, NOACs ment with OACs markedly decreases the risk of ischemic stroke have also been reported to pose a risk of bleeding complications, in patients with AF.2 Before the launch of NOACs, warfarin was which may be influenced by pharmacokinetic or pharmacody- namic interactions. Whereas an increased risk of bleeding in Received: May 27, 2020 Revised: July 10, 2020 warfarin has been well studied, there is still insufficient evidence Accepted: July 14, 2020 Corresponding author: Sun-Young Jung, PhD, College of Pharmacy, Chung-Ang about the risk of bleeding events associated with drug-drug University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea. interactions with NOACs. To date, several studies have assessed Tel: 82-2-820-5678, Fax: 82-2-816-7338, E-mail: [email protected] the numbers of potentially interacting drugs on the risk of com- •The authors have no potential conflicts of interest to disclose. posite bleeding events in patients using NOAC using databases © Copyright: Yonsei University College of Medicine 2020 in Taiwan,4 the United Kingdom,5 and German nursing homes.6 This is an Open Access article distributed under the terms of the Creative Com- However, interactions with drugs inhibiting platelet aggregation, mons Attribution Non-Commercial License (https://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro- including non-steroidal anti-inflammatory drugs (NSAIDs) and duction in any medium, provided the original work is properly cited. selective serotonin reuptake inhibitors (SSRIs), were not as- www.eymj.org 741 Use of NSAID or SSRI with NOAC Increases Bleeding sessed4 or showed conflicting results with previous studies.5,6 Study population NSAIDs are commonly used in short- or long-term treatment We conducted a nested case-control analysis among patients for several indications, including osteoarthritis and rheumatic with AF (ICD-10, I48) who were first prescribed NOACs during diseases. A Danish study reported that 21% of NOACs users took the study period from January 1, 2013, to December 31, 2017. concomitant NSAIDs,7 and a post hoc analysis of the RE-LY trial NOACs included in this study were apixaban, rivaroxaban, edox- revealed an increased risk of major bleeding associated with aban (factor Xa inhibitors), and dabigatran (direct thrombin in- NSAIDs in NOAC users.8 SSRIs are a first-line pharmaceutical hibitor). The date of the first NOAC prescription after AF was set treatment for major depressive disorder and anxiety disorders as the cohort entry. For each cohort population, at least 1 year and have relatively favorable safety profiles. However, studies of look-back period was applied before the first NOAC prescrip- have reported an increased risk of intracranial9 or gastrointesti- tion (2012.1.1.–2017.12.31.) to define new-users of NOACs with- nal (GI) hemorrhage10 associated with use of SSRIs. Furthermore, out any history of bleeding events. We also excluded patients combined use of NSAIDs and SSRIs concomitantly with NOACs diagnosed with cancer at least once and those who switched may pose an additional increase in the risk of bleeding. One from NOACs to warfarin during the study period. We determined study has shown that SSRIs combined with NSAIDs increases the cohort endpoint as 1) hospitalization or emergency depart- the risk of intracranial bleeding,11 and a meta-analysis has re- ment visit due to bleeding, 2) death, or 3) end of the study pe- ported a synergistic effect on GI bleeding with combined use of riod, whichever came first. NSAIDs and SSRIs.12 To date, however, population-based stud- In order to define an NOAC treatment episode, we allocated ies quantifying the degree of risk of bleeding associated with con- a grace period of 14 days. If a new prescription started less than comitant use of NSAIDs or SSRIs, especially for combined use 14 days from the end of the previous prescription and days of of the two drugs, remain scarce. supply, we defined the two prescriptions as the same treatment Concerning the risk of upper GI bleeding with NOACs, using episode, which began from the date of the previous prescrip- proton pump inhibitors (PPIs) when prescribing NOACs has tion and ended with the days of supply of the new prescription. been recommended in the 2018 European Heart Rhythm As- We defined the first NOACs treatment episode at cohort entry sociation guideline, especially in patients with a history of GI as the “incident episode” and the NOACs episode after exiting bleeding or ulcer and patients requiring concomitant use of the incident episode without hospitalization or emergency de- antiplatelet therapy.13 However, real-world data on the gastro- partment visit for bleeding as the “prevalent episode”. Thus, each protective effect in patients with NOACs, especially with con- cohort individual had only one incident episode and potentially comitant use of NSAIDs or SSRIs, is limited. several prevalent episodes. Accordingly, this study’s objective was to evaluate the risk of bleeding events in individuals taking concomitant NSAIDs or Definition of cases and controls SSRIs with NOACs after being diagnosed with AF and to iden- Cases were defined as patients that underwent hospitalization tify the risk of bleeding events. The second goal was to assess the or emergency department visit for major bleeding events. The risk of upper GI bleeding after the use of NSAIDs or SSRIs com- major bleeding events were categorized as upper GI bleeding, bined with PPIs. Finally, we performed subgroup analyses to lower GI bleeding, intracranial bleeding, and other bleedings, determine high-bleeding risk groups. including urinary tract bleeding, airway bleeding, and others, based on previous reports in the literature (Supplementary Ta- ble 1, only online).4,6,14 For each case, up to 20 controls at risk of MATERIALS AND METHODS the bleeding event were randomly selected by age (±5 years), sex, episode status, and duration from diagnosis of AF to the pre- Data source scription of NOACs (±1 year) using risk-set sampling. In the risk- This study used National Health Information Database (NHIS- set sampling, patients could serve as controls for multiple cas- 2019-1-402) made by National Health Insurance Service (NHIS), es, and patients were eligible to be selected as controls before a single-payer organization that is mandatory for all residents becoming a case. For each control, an index date was assigned in Korea. For this reason, the NHIS obtains information on pa- to have the same length of follow-up as that for a correspond- tient demographics, insurers’ payment coverage, medical use/ ing case. This approach resembles Cox regression with time- transactions, diagnoses, claims of procedures, and inpatient/ varying covariates and is reported to produce comparable and outpatient prescriptions. All diagnoses are coded according to unbiased estimates of hazard ratios compared by Cox regres- the international classification of disease, 10th revision, clinical sion on the full cohort, with superior computational efficiency modification (ICD-10 CM) established by the World Health Or- when studying time-dependent exposure, such as drug-drug ganization.
Load more

Recommended publications
  • Rheumatoid Arthritis (1 of 23)
    Rheumatoid Arthritis (1 of 23) 1 Patient presents w/ signs & symptoms of rheumatoid arthritis (RA) 2 4 DIAGNOSIS No Is RA confi rmed? ALTERNATIVE DIAGNOSIS Yes A Pharmacological therapy • Conventional synthetic disease-modifying anti-rheumatic drug (DMARD) (csDMARD) monotherapy [Methotrexate (preferred), Lefl unomide or Sulfasalazine] • Adjunctive therapy [corticosteroids, nonsteroidal anti-infl ammatory drugs (NSAIDs)] B Non-pharmacological therapy 3 CONTINUE TREATMENT Symptoms improved Yes • at 3 mth & treatment goal Consider decreasing achieved at 6 mth? dose if in sustained remission No A Pharmacological therapy A Add any one of the Pharmacological following: therapy 3 • TNF inhibitor1 or • Change to or add a No Yes • Non-TNF second csDMARD Are poor prognostic factors 1 B present? biological or Non-pharmacological • Jak-inhibitor therapy MIMS B Non- pharmacological therapy TREATMENT © See next page 1In patients who cannot use csDMARDs as comedication, interleukin-6 receptor antagonists & targeted synthetic DMARDs (tsDMARDs) have some advantages over other biological DMARDs (bDMARDs) Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B105 © MIMS 2020 Rheumatoid Arthritis (2 of 23) TREATMENT OF PATIENTS W/ POOR PROGNOSTIC FACTORS CONT’D CONTINUE 3 TREATMENT RHEUMATOID ARTHRITIS RHEUMATOID Symptoms improved • Yes Consider decreasing at 3 mth & treatment goal dose or increasing achieved at 6 mth? interval if in sustained remission No A Pharmacological therapy • Switch to another TNF inhibitor or non-TNF biological1 or • Jak-inhibitor B Non-pharmacological therapy 3 Symptoms improved Yes at 3 mth & treatment goal achieved at 6 mth? No 1In patients who failed one TNF inhibitor therapy, considerMIMS giving a second TNF inhibitor or changing to an agent from a diff erent class © Not all products are available or approved for above use in all countries.
    [Show full text]
  • Profile Profile Profile Profile
    127 4. Berl et al. Mechanism of allergic contact dermatitis from Piroxin; Fr. : Brexin; Cycladol; Feldene; Geldene; Inflacedt; 3-(4-[2-(1-p-Chlorobenzoyl-5-methoxy,2-methylindol-3-yia­ V, Proxalyoc; Zofora; Ger.: Brexidolt; Flexaset; Pirobeta; Piroflam; propacetamol: sensitization to activated N,N-diethylglycine. Contad cetoxy)eth)'i}piperazln-1-yl)propyt '4cbenzamldo-N,N,dipro­ 38: Pirox; Gr. : Bleduran; Brexin; Calmopyrol; Conzila; Feldene; Dermatitis I998; 185-8. pylglutaramate dimaieate. 5. Hersch M, et al. Effect of intravenous propacetamol on blood pressure in Fidinor; Flodeneu; Grecotens; Inflamase�N; Neo Axedil; Nilvo; febrile critically patients. Pharmacotherapy 2008; 28: I205-IO. Oximezin; Painrelipt�D; Pedifan; Propanol; Pyrcost; Reumaplus; 076.6 ill C�,HsaCIN50s,2C;H,04� 1 Ruvamed; Sinartrol; Valopon; Zerospasm; Zitumex; Hong Kong: Porphyria. The Drug Database for Acute Porphyria, com­ cinc� s ·-,57,�32�53�3 {,orogh:meracin); 59209-40-4 (.orogturn'eta­ CP-Pirox; Feldene; Mobilist; Piram-Dt; Piroxicat; Sefdene; piled by the Norwegian Porphyria Centre (NAPOS) and Synoxicamt; Vidapirocamt; Hung. : Brexin; Feldene; Flamexin; maleate). the Porphyria Centre Sweden, classifies propacetamol as Hotemin; Pirorheumt; India: Amida; Brexic; Camrox; Camsun; ATC - MOIA814. probably not porphyrinogenic; it may be used as a drug of Cycladol; Dolocare; Dolocip; Dolodil; Dolokam; Dololup; Dolo� ATC vet - 0MO/A8l4. first choice and no precautions are needed.1 nex; Dolopir; Doloswift; Dupox; Estcom; Felcam; Feldex; Flex� UN!/ - F2PUN24B8C ar; Kemonex; Lincitrax; Medicam; Meloxi; Micropec; Mobicam; I. The Drug Database for Acute Porphyria. Available at: http:l/www. drugs-porphyria.org (accessed II !10/11) Mobidin; Movon; Noxicam-MD; Pam; Panorox; Pirox; Suganril; ; Profile Indon.: Faxident; Felcam; Feldene; Infeld; Kifadene; Lanareu­ Proglumetacin maleate, an indoleacetic add derivative P epa at ons ma; Licofel; Maxicamt; Pirocam; Pirodenet; Pirofel; Rexicam; .........r r .......i ...............
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Protocol Synopsis
    Risk of Upper Gastrointestinal Complications in Users of Nonsteroidal Anti-inflammatory Drugs Study Protocol—V2.0 (Final) October 19, 2009 Prepared by Jordi Castellsague Susana Perez-Gutthann RTI Health Solutions E-mail: [email protected] Federica Pisa, MD, MStat Fabio Barbone, MD, DrPH Udine University, AOUD Udine Institute of Hygiene and Epidemiology E-mail: [email protected] RTI-HS Project No.: 0301655 PROTOCOL APPROVAL SIGNATURE PAGE Project Title : Risk of Upper Gastrointestinal Complications in Users ofNonsteroidal Anti-inflammatory Drugs RTI-HS Project 0301655 Final Appro val Date: October 22,2009 Authors: Jordi Castellsague, MD, MPH; Susana Perez-Gutthann, MD, PhD (RTI­ HS) Fede rica Pisa, MD, MStat; Fabio Barbone, MD, DrPH (Udine University, AOUD Udine) Version: Version 2.0 Final Version Date: October 19, 2009 The following people have reviewed the protocol and give their approval: Susana Perez-Gutthann, MD, PhD Date Global Head Epidemiology RTI Health Solutions / Fabio Barbone, MD, D H Signature Date Director, Institute of Hygiene and Epidemiology University of Udine ii TABLE OF CONTENTS 1 STUDY SYNOPSIS ............................................................................................ 1 2 BACKGROUND ................................................................................................. 4 3 KEY ROLES AND RESPONSIBILITIES ............................................................ 5 3.1.1 Financial Sponsorship ....................................................................................................
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Polmacoxib Item No. 17509 OO CAS Registry No.: 301692-76-2 Formal Name: 4-[3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl- S NH 4-oxo-2-furanyl]-benzenesulfonamide 2 MF: C H FNO S 18 16 4 O FW: 361.4 Purity: ≥98% F UV/Vis.: λmax: 238, 320 nm Supplied as: A crystalline solid O Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Polmacoxib is supplied as a crystalline solid. A stock solution may be made by dissolving the polmacoxib in the solvent of choice. Polmacoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of polmacoxib in ethanol is approximately 5 mg/ml and approximately 20 mg/ml in DMSO and DMF. Polmacoxib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, polmacoxib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Polmacoxib has a solubility of approximately 0.5 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Polmacoxib is an inhibitor of cyclooxygenase 2 (COX-2) and the carbonic anhydrase subtypes I (CAI) and 1 CAII. It inhibits COX-2 in the absence of carbonic anhydrase II with an IC50 value of 40 nM, which increases by approximately 4- and 17-fold in the presence of a CAII at a molar ratio of 1:1 and 1:5, respectively.2 It also inhibits CAI and CAII (IC50s = 210 and 95 nM, respectively).
    [Show full text]
  • Analgesic & Rheumatology
    Recommendations of the SEC (Analgesic & Rheumatology) made in its 72nd meeting held on 24.06.2021 & 25.06.2021 at CDSCO HQ New Delhi. File Name & Recommendations Agenda Drug Name, Firm Name No Strength New Drugs Division ND/MA/21/000076 M/s Hetero Labs Ltd. The firm presented their proposal of Polmacoxib 2 mg Fresh Application Phase III clinical trial protocol capsules along with BE study protocol before committee. After detailed deliberation, the 1. committee recommended for grant of permission to conduct the BE study. The firm should present the results of BE study before committee for further consideration of phase III clinical trial protocol. Biological Division BIO/CT- The firm presented their proposal 18/FF/2021/24609- for marketing authorization and Belimumab (Marketing Authorization)- local clinical trial waiver based on Belimumab the results of GCT including sub set analysis on 66 Indian patients. The committee noted that the drug is not an unmet need in the country. M/s. GSK Further, the data presented by the 2. Pharmaceuticals firm in Indian sub-set is limited and Ltd. in different route of administration (intravenous) while the firm is seeking MA for subcutaneous route. After detailed deliberation, the committee did not recommend for grant of approval for marketing authorization. BIO/CT21/FF/2021/246 M/s Reliance Life The firm presented their proposal 79- Denosumab Sciences Pvt ltd for marketing authorization along 60mg/ml with the results of Phase-III clinical trial. 3. The committee noted that the Phase III trial was approved
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Directory of Korean Pharmaceutical Industry 2016
    2016 Directory of Korean Pharmaceutical Industry Contents 1. Greeting ������������������������������������������������������������������������������������������������������������������������������������������� 4 2. Overview of the Korean Pharmaceutical Industry ������������������������������������������������������������ 6 1) Current Status 2) Production Management System 3) Development of New Drugs 4) R&D Reinforcement 5) Biopharmaceuticals 6) Globalization 7) Korean Pharmaceutical Industry Vision - PHARMA 2020 3. Directory of Pharmaceutical Companies �������������������������������������������������������������������������� 13 · Regular Members(2015. 4) A~D ���������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 14 E~J ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 66 K~P �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 110 R~Y �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 158 · Associated Members(2015. 4) C~G ���������������������������������������������������������������������������������������������������������������������������������������������������������������������������
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]